Status:
COMPLETED
Triple Antigen vs Monoantigen Immunotherapy for Warts
Lead Sponsor:
Zagazig University
Conditions:
Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts
Eligibility:
All Genders
10-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Warts can be resistant to treatment or return despite the use of many therapeutic modalities. Combining immunotherapy might contribute to better response rates, particularly in recalcitrant warts, whi...
Detailed Description
This study included 160 patients with multiple (\>3 warts) recalcitrant (at least 6 months duration and who did not respond to at least 2 treatment modalities) warts of different sites, size and durat...
Eligibility Criteria
Inclusion
- Multiple (\> 3 warts) recalcitrant (at least 6 months duration and who did not respond to at least 2 treatment modalities) warts of different sites, size and duration
Exclusion
- Patients with acute febrile illness or past history of asthma.
- Allergic skin disorders such as generalized eczema and urticaria.
- Past history of meningitis or convulsions.
- Pregnancy or lactation.
Key Trial Info
Start Date :
November 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 15 2021
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05254561
Start Date
November 20 2020
End Date
November 15 2021
Last Update
February 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig university
Zagazig, Sharqia Province, Egypt, 44519